Stay updated on Apalutamide Study in High-Risk Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Apalutamide Study in High-Risk Prostate Cancer Clinical Trial page.

Latest updates to the Apalutamide Study in High-Risk Prostate Cancer Clinical Trial page
- Check3 days agoChange DetectedA new revision entry 'Revision: v3.6.2' has been added to the record history, reflecting the latest release notes for the page. The previous 'Revision: v3.6.0' entry has been removed from the history.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedRecord history now shows the study is no longer recruiting participants. It also includes an updated release note (Revision: v3.6.0) and the removal of the prior revision (v3.5.5), reflecting administrative updates to the record.SummaryDifference0.1%

- Check25 days agoChange DetectedThe history page now shows a new site revision (v3.5.5), replacing the previous v3.5.4, indicating a backend/UI update to the ClinicalTrials.gov interface rather than a change to the study record itself.SummaryDifference0.0%

- Check46 days agoChange DetectedA new version entry on 2026-05-08 was added that includes a Study Status update and a Revision: v3.5.4. The previous revision entry for v3.5.3 (dated 2026-04-13) was removed from the history.SummaryDifference0.2%

- Check67 days agoChange DetectedThe page’s UI revision/version marker has been updated from v3.5.2 to v3.5.3, indicating a change to the ClinicalTrials.gov interface release rather than study record information.SummaryDifference0.0%

- Check75 days agoChange DetectedA new version entry on 2026-04-13 adds Contacts/Locations and Study Status and updates the revision to v3.5.2, replacing the prior v3.5.0.SummaryDifference0.2%

Stay in the know with updates to Apalutamide Study in High-Risk Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Apalutamide Study in High-Risk Prostate Cancer Clinical Trial page.